FIVE DOSE TRIAL OF ABX IL8 IN TREATMENT OF SEVERE PLAQUE PSORIASIS

ABX-IL-8是在转基因小鼠中产生的人源化单克隆抗体。该抗体对IL-8具有高亲和力，并且可以中和IL-8，如在几种测定系统中所证明的。 该抗体抑制与嗜中性粒细胞的结合，抑制IL-8诱导的钙流，并抑制MAC-1表达、弹性蛋白酶释放和趋化性。 Krueger博士通过在实验系统中证明，移植到裸鼠上的银屑病患者的未受影响的皮肤在注射IL-8时产生银屑病样病变，为该方案进行了开发工作。 这种作用通过施用ABX-IL-8完全阻断。 这些动物数据表明，针对IL-8的抗体可能是治疗斑块期银屑病的有效方法。根据对GCRC进行的研究，确定了药物的安全性，然后确定了适当的剂量范围。 这种药物在治疗斑块期银屑病中被证明是非常有效的，描述这种疗法的有益效果的手稿现在正在准备中。

ABX-IL-8 is a humanized monoclonal antibody generated in transgenic mice. The antibody has a high affinity for IL-8, and can neutralize IL-8, as demonstrated in several assay systems. The antibody inhibits binding to neutrophils, inhibits IL-8-induced calcium flux, and inhibits MAC-1 expression, elastase release, and chemotaxis. Dr. Krueger did the developmental work for this protocol by demonstrating in an experimental system that unaffected skin from patients with psoriasis, grafted onto nude mice, generated psoriasis-like lesions when IL-8 was injected. This effect was totally blocked by administering ABX-IL-8. These animal data suggest that an antibody against IL-8 might be an effective method of treating plaque-phase psoriasis. From the study done on the GCRC, safety of the drug was determined, and then appropriate dosing ranges established. The drug proved remarkably effective in the treatment of plaque-phase psoriasis, and a manuscript describing the beneficial effects of this therapy is now in preparation.